Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
BMJ Case Rep ; 15(12)2022 Dec 09.
Artigo em Inglês | MEDLINE | ID: mdl-36593635

RESUMO

Intravesical BCG therapy is commonly used to treat superficial bladder cancer. Although various complications associated with this therapy have been reported, tuberculous spondylitis is uncommon. Here, we report a rare case of tuberculous spondylitis that occurred after intravesical BCG therapy for bladder cancer. A man in his 80s received BCG immunotherapy for bladder cancer and developed low back pain after treatment. Remarkably, he presented with neurological symptoms. Spondylitis was suspected on imaging. CT-guided biopsy was performed to confirm the diagnosis. Consequently, Mycobacterium bovis was identified as the causative pathogen by multiplex PCR. Multidrug therapy, administered for several months, was ineffective. Therefore, surgery was performed through an anterior approach. The symptoms, including low back pain, improved and postoperative C reactive protein tests were within the normal range. Tuberculous spondylitis following BCG therapy should be considered in cases with a history of bladder cancer treatment.


Assuntos
Vacina BCG , Dor Lombar , Mycobacterium bovis , Espondilite , Tuberculose da Coluna Vertebral , Neoplasias da Bexiga Urinária , Humanos , Masculino , Administração Intravesical , Vacina BCG/efeitos adversos , Vacina BCG/uso terapêutico , Quimioterapia Combinada , Hansenostáticos/uso terapêutico , Dor Lombar/diagnóstico por imagem , Dor Lombar/etiologia , Espondilite/diagnóstico , Espondilite/microbiologia , Tuberculose da Coluna Vertebral/diagnóstico , Tuberculose da Coluna Vertebral/microbiologia , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/cirurgia , Neoplasias da Bexiga Urinária/complicações , Idoso de 80 Anos ou mais
2.
J Bone Miner Metab ; 23(1): 90-4, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15616900

RESUMO

There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy. In this study, we report a case of osteoporosis in a man with leprosy, treated by oral administration of risedronate and alfacalcidol. An 82-year-old man with leprosy presented to our hospital with chronic back pain, due to osteoporosis, in July 2002. To prevent the progression of osteoporosis, oral administration of risedronate and alfacalcidol was started for this patient. An increase in forearm BMD and a decrease in the level of urinary crosslinked N-telopeptides of type I collagen (NTx) were observed in January 2003. The patient suffered a trochanteric fracture of the proximal femur at the end of March 2003. Surgical treatment with a sliding-screw plate was performed 5 days after the injury. Complete bony union of the right proximal femur was confirmed by radiography in July 2003. The above findings suggested that the treatment with risedronate and alfacalcidol contributed to the increase in BMD; however, the treatment did not prevent fracture due to osteoporosis in this male patient with leprosy.


Assuntos
Ácido Etidrônico/análogos & derivados , Ácido Etidrônico/uso terapêutico , Fraturas do Quadril/complicações , Hidroxicolecalciferóis/uso terapêutico , Hanseníase/complicações , Osteoporose/complicações , Osteoporose/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Densidade Óssea/fisiologia , Ácido Etidrônico/administração & dosagem , Fêmur/diagnóstico por imagem , Fêmur/patologia , Fraturas do Quadril/diagnóstico por imagem , Fraturas do Quadril/tratamento farmacológico , Fraturas do Quadril/cirurgia , Humanos , Hidroxicolecalciferóis/administração & dosagem , Hanseníase/tratamento farmacológico , Hanseníase/microbiologia , Hanseníase/patologia , Masculino , Mycobacterium leprae/fisiologia , Osteoporose/microbiologia , Radiografia , Ácido Risedrônico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA